Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT00836160
NCT00836160CompletedNot Applicable

Comparing Efficacy Between Anti-microtubule and Non-anti-microtubule as 3th Therapy After 2nd Line EGFR-TKI Therapy

AstraZeneca1 site in 1 country36 target enrollmentStarted: August 2009Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
36
Locations
1
Primary Endpoint
PFS of the third-line therapy
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

This is an observational prospective study that investigates only daily practice. The prescription of anti-cancer medicine is separated from the decision to include the patient in this study. In addition, the assignment of the patient to a particular therapy or therapeutic strategy is not decided in advance by this study protocol, but falls within current practice.

The patient who fulfils eligible criteria will be enrolled when starts to receive the second-line EGFR-TKI therapy. The frequency of tumor response evaluation by RECIST criteria follows the investigator's discretion as daily practice.

Study Design

Study Type
Observational
Time Perspective
Prospective

Eligibility Criteria

Ages
20 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •At least one measurable lesion according to RECIST criteria
  • •Histologically or cytologically confirmed NSCLC of adeno histology
  • •Locally progressed or metastasized on or after first-line chemotherapy. The imaging evidence of disease progression can be either chest X ray, CT or MRI assessment on measurable lesions. If no measurable lesion is available, evaluable lesions are acce

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

PFS of the third-line therapy

Time Frame: 9 months

Secondary Outcomes

  • Overall objective tumor response (complete response [CR] + partial response [PR]) of the third-line therapy by RECIST criteria(9 months)

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials

Completed
Not Applicable
Prospective Non-Interventional Observational Study of Use of TRIUMEQ and Corresponding Monitoring Measures in Clinical Practice in GermanyHIV Infections
NCT02342769ViiV Healthcare403
Unknown
Not Applicable
Nonintervention Study on Peritoneal Metastasis of Stage IV Gastric CancerStage IV Gastric Cancer With Metastasis
NCT03237507Harbin Medical University110
Recruiting
Unknown
This Study Focuses On The Management Of Frozen Shoulder Through Homoeopathic Medicines along with physiotherapy.
CTRI/2023/12/060611Dr. Vidita Rathva
Completed
Not Applicable
Observational Non-interventional Study (Anwendungsbeobachtung) With Aptivus® (Tipranavir) in HIV-infected Patients.HIV Infections
NCT00531206Boehringer Ingelheim65
Completed
Not Applicable
Clinical efficacy of second generation laryngeal mask airways
CTRI/2018/03/012272Kokilaben Dhirubhai Ambani Hospital and medical research institute120